Table 1.
Year | Hotspots | Disease assessment to different IRBLs | |||
---|---|---|---|---|---|
IRBLta2-Re | IRBLta-Zh | IRBLta-CT2 | LTH | ||
2014 | Cankuzo | R | S | – | S |
Gisha | R | S | – | S | |
Rugombo | R | MS | – | S | |
Bohol | – | – | – | – | |
2015 | Cankuzo | R | S | MS | S |
Gisha | R | S | MS | S | |
Rugombo | R | MS | S | S | |
Bohol | – | – | – | – | |
2016 | Cankuzo | MR | S | S | S |
Gisha | R | MS | S | S | |
Rugombo | MR | S | S | S | |
Bohol | R | – | R | S | |
2017 | Cankuzo | S | S | MS | S |
Gisha | MS | MS | MS | S | |
Rugombo | MS | MS | MS | S | |
Bohol | MR | – | S | S | |
2018 | Cankuzo | S | S | MS | S |
Gisha | MS | MS | MS | S | |
Rugombo | S | S | S | S | |
Bohol | R | – | MS | S |
R resistant. S susceptible. MR moderate resistant. MS moderate susceptible. –: no data